Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage

LEXINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Compa

Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock?

Hsbc Holdings PLC acquired a new position in Keros Therapeutics, Inc. (NASDAQ: KROS) in the second q

Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium

Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps

Dimensional Fund Advisors LP lifted its holdings in Keros Therapeutics, Inc. (NASDAQ: KROS) by 453.9

Empowered Funds LLC raised its holdings in Keros Therapeutics, Inc. (NASDAQ: KROS) by 142.2% during

Keros posts a wider Q2 loss as revenues fall to zero, while cash runway into H1 2028 and rinvatercep

Wells Fargo analyst Benjamin Burnett maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight

Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.45) per share which missed the ana

LEXINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Compan

ELRiSE MDS is a Phase 3, multicenter, open-label, randomized trial to compare the efficacy and safet

LEXINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS

ITRG, BEEM and KROS have been added to the Zacks Rank #5 (Strong Sell) List on July 30, 2026.

LEXINGTON, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Compan

Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2

LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS

Keros faces a volatile setup after its Q1 miss, with a longer cash runway and leaner costs balanced

Keros is shifting toward rinvatercept-led neuromuscular development, with phase II plans, early huma

Keros heads into 2026 with rinvatercept catalysts in DMD and ALS as investors watch phase II plans,

KROS posts a wider Q1 loss as revenues fall due to the absence of license revenues. The company adva

Keros Therapeutics, Inc. (KROS) came out with a quarterly loss of $1.21 per share versus the Zacks C

Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.21) per share which missed the ana

LEXINGTON, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company

Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage

Wells Fargo analyst Benjamin Burnett maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight

Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(0.86) per share which missed the ana

B of A Securities analyst Jason Zemansky maintains Keros Therapeutics (NASDAQ:KROS) with a Neutra

U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday. S

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company p

U.S. stocks traded mostly mixed, with the Dow Jones index gaining more than 100 points on Monday. H

  On Wednesday, 311 stocks hit new 52-week lows.

  On Tuesday, 647 companies set new 52-week lows.

  On Monday, 369 companies set new 52-week lows.

  On Tuesday, 386 stocks made new 52-week lows.

  During the session on Thursday, 461 stocks hit new 52-week lows.

Gainers Advanced Health Intelligence Ltd. (NASDAQ: AHI) shares jumped 144.5% to $0.7827.

Upgrades

  On Thursday, 216 stocks hit new 52-week lows.

  On Tuesday, 951 companies hit new 52-week lows.

  On Friday, 422 stocks made new 52-week lows.

Gainers Bright Green Corp. (NASDAQ: BGXX) jumped 90.5% to close at $48.08 on Wednesday. Bright Gr